Download PDF
Thromb Haemost 2020; 120(03): 484-494
DOI: 10.1055/s-0039-3401823
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Arjun K. Pandey
1   Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
,
Ke Xu
2   Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
,
Li Zhang
3   Division of Cardiac Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
,
Saurabh Gupta
3   Division of Cardiac Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
4   Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
,
John Eikelboom
5   Population Health Research Institute, Hamilton, Ontario, Canada
6   Division of Hematology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Olivia Cook
7   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
William F. McIntyre
4   Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
5   Population Health Research Institute, Hamilton, Ontario, Canada
8   Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Renato D. Lopes
9   Duke Clinical Research Institute, Durham, North Carolina, United States
10   Duke University School of Medicine, Durham, North Carolina, United States
,
Mark Crowther
4   Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
6   Division of Hematology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Emilie P. Belley-Côté
4   Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
5   Population Health Research Institute, Hamilton, Ontario, Canada
8   Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Richard P. Whitlock
3   Division of Cardiac Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
4   Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
5   Population Health Research Institute, Hamilton, Ontario, Canada
› Author Affiliations Funding None.
Further Information

Publication History

14 August 2019

01 November 2019

Publication Date:
15 January 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Background Western guidelines recommend an international normalized ratio (INR) range of 2 to 3 when using warfarin for stroke prevention in atrial fibrillation (AF), but lower INR ranges are frequently used in East Asia. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) in AF patients comparing the effect of lower versus standard INR targets on thromboembolism, major bleeding, and mortality.

Methods We searched Western databases including Cochrane CENTRAL, Medline, and Embase as well as Chinese databases including SinoMed, CNKI, and Wanfang Data. We pooled risk ratios (RRs) using random-effects model. We grouped INR targets in two ways: (1) any study-specific lower versus standard targets and (2) INR ranges of approximately 1.5 to 2 versus 2 to 3.

Results Seventy-nine RCTs (n = 12,928) met eligibility criteria: 74 (n = 11,322) from East Asia and 5 (n = 1,606) from Western countries. Compared with standard targets, lower INR ranges were associated with higher rates of thromboembolism (76 RCTs, n = 12,577: 7.1% vs. 4.4%, RR 1.50, 95% confidence interval [CI] 1.29–1.74, I 2 = 0%), lower rates of major bleeding (61 RCTs, n = 10,815: 2.2% vs. 4.4%, RR 0.54, 95% CI 0.44–0.67, I 2 = 0%), and similar mortality (32 RCTs, n = 7,327: 4.8% vs. 5.2%, RR 1.00, 95% CI 0.85–1.19, I 2 = 0%). Results were similar when comparing target ranges of approximately 1.5 to 2 versus 2 to 3.

Conclusion Moderate quality evidence suggests lower INR targets reduce bleeding but increase thromboembolism in AF. The data are dominated by East-Asian studies, limiting generalizability to Western populations. Until higher quality data demonstrate otherwise, an INR range of 2 to 3 should remain standard for thromboembolic prophylaxis in AF.

Keywords

clinical trials - oral anticoagulants - stroke - prevention - atrial fibrillation

Supplementary Material

 

  • References

  • 1 Huisman MV, Rothman KJ, Paquette M. , et al; GLORIA-AF Investigators. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol 2017; 69 (07) 777-785
    PubMedGoogle Scholar
  • 2 Hart RG, Aguilar MI. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. J Thromb Thrombolysis 2008; 25 (01) 26-32
    CrossrefPubMedGoogle Scholar
  • 3 You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. Br J Clin Pharmacol 2005; 59 (05) 582-587
    CrossrefPubMedGoogle Scholar
  • 4 Inoue H, Okumura K, Atarashi H. , et al; J-RHYTHM Registry Investigators. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J 2013; 77 (09) 2264-2270
    CrossrefPubMedGoogle Scholar
  • 5 Du X, Ma C, Wu J. , et al; CAFR Investigators. Rationale and design of the Chinese atrial fibrillation registry study. BMC Cardiovasc Disord 2016; 16 (01) 130
    CrossrefPubMedGoogle Scholar
  • 6 Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111 (05) 789-797
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Hori M, Connolly SJ, Zhu J. , et al; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44 (07) 1891-1896
    CrossrefPubMedGoogle Scholar
  • 8 Wong KS, Hu DY, Oomman A. , et al; Executive Steering Committee and the ROCKET AF Study Investigators. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 2014; 45 (06) 1739-1747
    CrossrefPubMedGoogle Scholar
  • 9 Goto S, Zhu J, Liu L. , et al; ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J 2014; 168 (03) 303-309
    CrossrefPubMedGoogle Scholar
  • 10 Yamashita T, Koretsune Y, Yang Y. , et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation - an ENGAGE AF-TIMI 48 subanalysis. Circ J 2016; 80 (04) 860-869
    CrossrefPubMedGoogle Scholar
  • 11 Reynolds MW, Fahrbach K, Hauch O. , et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. Chest 2004; 126 (06) 1938-1945
    CrossrefPubMedGoogle Scholar
  • 12 Gupta S, Belley-Cote EP, Sarkaria A. , et al. International normalized ratio targets for left-sided mechanical valve replacement. Thromb Haemost 2018; 118 (05) 906-913
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Pandey A, Belley-Cote E, Chu A. , et al. The safety and efficacy of lower compared to higher INR targets in adult patients with atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. PROSPERO 2018. CRD42018103272. Available at: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018103272 . Accessed November 20, 2019
    PubMedGoogle Scholar
  • 14 Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at: www.covidence.org . Accessed November 20, 2019
    PubMedGoogle Scholar
  • 15 Higgins JP, Altman DG, Gøtzsche PC. , et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
    CrossrefPubMedGoogle Scholar
  • 16 Manager R. (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014
    PubMed
  • 17 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (03) 177-188
    CrossrefPubMedGoogle Scholar
  • 18 Guyatt GH, Oxman AD, Vist GE. , et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336 (7650): 924-926
    CrossrefPubMedGoogle Scholar
  • 19 Chen KP, Huang CX, Huang DJ. , et al. Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: a prospective, multi-center, randomized, controlled study. Chin Med J (Engl) 2012; 125 (24) 4355-4360
    PubMedGoogle Scholar
  • 20 Chen X, Wan R, Jiang W. , et al. Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation. Exp Ther Med 2013; 6 (02) 413-418
    CrossrefPubMedGoogle Scholar
  • 21 Wu J, Wang J, Jiang S. , et al. The efficacy and safety of low intensity warfarin therapy in Chinese elderly atrial fibrillation patients with high CHADS2 risk score. Int J Cardiol 2013; 167 (06) 3067-3068
    CrossrefPubMedGoogle Scholar
  • 22 Hellemons BSP, Langenberg M, Lodder J. , et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999; 319 (7215): 958-964
    CrossrefPubMedGoogle Scholar
  • 23 Klein KL, Berdeaux DH, Milhollen JD. , et al. Equal effectiveness of very-low-intensity anticoagulation and standard low-intensity anticoagulation: a pilot study. South Med J 1995; 88 (11) 1136-1139
    CrossrefPubMedGoogle Scholar
  • 24 Pengo V, Cucchini U, Denas G. , et al. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. Thromb Haemost 2010; 103 (02) 442-449
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Yamaguchi T. ; Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Stroke 2000; 31 (04) 817-821
    CrossrefPubMedGoogle Scholar
  • 26 Pengo V, Barbero F, Biasiolo A, Pegoraro C, Noventa F, Iliceto S. Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment. Thromb Haemost 2003; 89 (04) 760-764
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Pérez-Gómez F, Alegría E, Berjón J. , et al; NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004; 44 (08) 1557-1566
    CrossrefPubMedGoogle Scholar
  • 28 Bai Q, Wang J. Low-dose warfarin in persistent atrial fibrillation. Med J West China 2007; 5: 825-826
    PubMedGoogle Scholar
  • 29 Bu Q, Jiao D, Li F. Effectivity and safety of low-intensity warfarin anticoagulation in elderly patients with nonvascular atrial fibrillation. Clin J Med Offic 2015; 43 (09) 969-973
    PubMedGoogle Scholar
  • 30 Chen JL, Weiss S, Heyman MB, Vittinghoff E, Lustig R. Pilot study of an individually tailored educational program by mail to promote healthy weight in Chinese American children. J Spec Pediatr Nurs 2008; 13 (03) 212-222
    CrossrefPubMedGoogle Scholar
  • 31 Chen X, Zhang H, Zhen R. , et al. The prognostic effect of different warfarin anticoagulation on patients with paroxysmal non-valvular atrial fibrillation. Chin. J Evid Based Med 2009; 9 (05) 517-521
    PubMedGoogle Scholar
  • 32 Chen Y. Efficacy and safety of different dose of warfarin in paroxysmal atrial fibrillation in elderly patients. J Bethune Military Med Coll 2016; 14 (01) 71-72
    PubMedGoogle Scholar
  • 33 Chen J, Hong H, Huang F. Different intensity anticoagulant therapy of warfarin in patients with nonvalvular atrial fibrillation. Fujian Med J 2014; 36 (04) 97-99
    PubMedGoogle Scholar
  • 34 Dong M, Xu G, Zhu J, Zhang J, Wu X. Effect of different international normalized ratio on the risk of cerebral ischemic stroke and bleeding in atrial fibrillation patients with chronic renal failure. Clin Medication J 2015; 13 (04) 25-27
    PubMedGoogle Scholar
  • 35 Dong Y, Li S. The effect of low-dose warfarin, aspirin, and standard-dose warfarin on thrombosis in non-valvular atrial fibrillation patients. Master's thesis, Jilin University; 2004
    PubMedGoogle Scholar
  • 36 Duan Y. Low-dose warfarin for anticoagulation in non-valvular atrial fibrillation. Asia-Pacific Traditional Med 2010; 6 (07) 58-59
    PubMedGoogle Scholar
  • 37 Gao Y, Cheng X, Zhang H, Fu R, Guo G, Wu Z. Antithrombotic therapy in nonvalvular atrial fibrillation: aspirin and different anticoagulant intensity of warfarin. Shandong Yiyao 2007; 47 (22) 15-16
    PubMedGoogle Scholar
  • 38 Gao H, Zhang Y, Wang Y. Treatment of permanent atrial fibrillation with thrombolysis analysis of 151 cases. J Hainan Med Coll 2009; 15 (03) 256-261
    PubMedGoogle Scholar
  • 39 Guan X, Liu J. Efficacy and safety analysis of low intensity warfarin in the elderly patients with atrial fibrillation. Master's thesis, Dalian Medical University; 2017
    PubMedGoogle Scholar
  • 40 Guo F, Qiu Y, Chen G. Clinical study of warfarin for thromboembolism prevention in older patients with nonvalvular atrial fibrillation. Chinese J Thromb Hemost 2016; 22 (04) 367-369
    PubMedGoogle Scholar
  • 41 Han Y. Efficacy and safety of warfarin in non-valvular atrial fibrillation. World Health Digest 2011; 17: 102-103
    PubMedGoogle Scholar
  • 42 Huang S, Lin T, Liu Y. Different intensity of warfarin for antithrombosis in nonvalvular atrial fibrillation. J Pract Med 2009; 25 (24) 4213-4214
    PubMedGoogle Scholar
  • 43 Huang J, Li H, Lu Y, Fu C, Yan H, Chen X. Comparison of antithrombotic efficacy and safety of different doses of warfarin and aspirin in elderly patients with persistent atrial fibrillation. South China J Cardiovasc Dis 2012; 18 (04) 357-359
    PubMedGoogle Scholar
  • 44 Huang H, Zha S, Liu X, Bo X, Feng L. Warfarin anticoagulation in elderly patients with atrial fibrillation: evaluation by occurrence of adverse cardiovascular events. J Diagn Concepts Pract 2016; 15 (05) 513-516
    PubMedGoogle Scholar
  • 45 Ji T. Different anticoagulation intensity warfarin's influence on the prognosis of patients with paroxysmal atrial fibrillation analysis. Chinese J Frontiers Med Sci 2014; 6 (08) 145-147
    PubMedGoogle Scholar
  • 46 Jiang X, Chen G. Low-dose warfarin in nonvalvular atrial fibrillation patients with stroke. Master's thesis, Fujian Medical University; 2011
    PubMedGoogle Scholar
  • 47 Lai C. Efficacy of different antithrombotic therapies in elderly patients with atrial fibrillation. Modern Journal of Integrated Traditional Chinese and Western Medicine 2014; 23 (26) 2910-2911
    PubMedGoogle Scholar
  • 48 Lei J, Xue R. Efficacy and safety of different dose of warfarin in elderly nonvalvular atrial fibrillation patients with stable coronary artery disease. Chongqing Medicine. 2018; 47 (01) 114-117
    PubMedGoogle Scholar
  • 49 Li B, Zhong Z. Low intensity warfarin for preventing thrombotic events in nonvalvular atrial fibrillation patients with risk factors of thrombosis. J Guangdong Med Coll 2005; 3: 273-274
    PubMedGoogle Scholar
  • 50 Li X, Kuang Y, Wang Y. Effect of different intensity warfarin in elderly patients with atrial fibrillation. Prevention and Treatment of Cardio-Cerebral-Vascular Disease 2005; 4: 26-28
    PubMedGoogle Scholar
  • 51 Li R, Cao X. The clinical research for safety and availability of low-intensity anticoagulation with warfarin therapy in AF patients with high risk of hemorrhage. Master's thesis, Hebei Medical University; 2013
    PubMedGoogle Scholar
  • 52 Li H, Liu Y, Zhang P. , et al. Analysis of normalized anticoagulant therapy for patients with non-valvular atrial fibrillation in clinical application. Prac J Med Pharm 2016; 33 (07) 584-585
    PubMedGoogle Scholar
  • 53 Lian Y, Zhang Y, Yang M. , et al. Application of warfarin in treating atrial fibrillation. Zhongguo Shiyong Neike Zazhi 2004; 24 (05) 285-286
    PubMedGoogle Scholar
  • 54 Liang W, Chen X, Xian H. Clinical study of warfarin in prevention of thrombo-embolism among patients with atrial fibrillation. Int J Emerg Crit Care Med. 2004; 1 (06) 408-410
    PubMedGoogle Scholar
  • 55 Liu J, Zhang X. Effect on bleeding and D-dimer level of different intensity warfarin in nonvalvular atrial fibrillation. Cardiovasc Dis J Integrated Traditio Chinese Western Med (Electronic) 2015; 3 (15) 85-86
    PubMedGoogle Scholar
  • 56 Liu Y, Liu L, Zhang T. Small dosage of warfarin for patients with non-valvular atrial fibrillation and high risk of cerebral embolism. IMHGN 2018; 24 (06) 883-885
    PubMedGoogle Scholar
  • 57 Liu BT, Jing Y. Application of low intensity warfarin in patients with nonvalvular atrial fibrillation at high risk of cerebral embolism. Hainan Med J. 2017; 28 (02) 209-210
    PubMedGoogle Scholar
  • 58 Liu H, Zhang W, Dai M. Antithrombotic effect of warfarin with low anticoagulant strength on nonvalvular atrial fibrillation. China Modern Doctor. 2017; 55 (26) 37-39
    PubMedGoogle Scholar
  • 59 Liu M, Hou W, Liu Y. , et al. The study on anticoagulation intensity of warfarin to prevent atrial fibrillation patients with thrombotic disease. Chinese J Thromb Hemost 2009; 15 (02) 61-62
    PubMedGoogle Scholar
  • 60 Liu S, Zhu A, Gao S. Prevention of stroke in nonvalvular atrial fibrillation patients treated with different anticoagulant intensity warfarin. Pract J Cardiac Cerebral Pneumal Vasc Dis 2012; 20 (02) 277-278
    PubMedGoogle Scholar
  • 61 Liu X, Huang H, Feng L. , et al. Different intensity warfarin anticoagulation therapy for elderly stable coronary heart disease patients with atrial fibrillation. Chin J Geriatr Heart Brain Vessel Dis. 2016; 18 (02) 132-135
    PubMedGoogle Scholar
  • 62 Lu T, Song S, Liu Y, Song X. Effect of low anticoagulant intensity of warfarin on thrombo-embolism in patients with nonvalvular atrial fibrillation. Zhongyuan Yikan 2006; 33 (15) 20-21
    PubMedGoogle Scholar
  • 63 Ma Y, Zheng Z. An observation of antithrombotic effect and safety of warfarin and aspirin in the therapy for patients with nonvalvular atrial fibrillation. Acta Acad Med Jiangxi 2007; 47 (05) 59-64
    PubMedGoogle Scholar
  • 64 Ma C, Xie P, Zhang W, Ying Y, Zhang T, Chen X. Ultra-low intensity warfarin anticoagulation in octogenarians with nonvalvular atrial fibrillation and high risk of hemorrhage. J Electrocardiol 2015; 34 (01) 25-27
    PubMedGoogle Scholar
  • 65 Mao B, Chen L, Luo Y. Evaluation of ideal dosage of warfarin in treatment of anticoagulation in patients with atrial fibrillation. Prevent Treatment Cardio Cerebral Vasc Dis 2006; 6 (03) 153-154
    PubMedGoogle Scholar
  • 66 Peng Q, Xu T. Influence of intensity of warfarin anticoagulation therapy on treatment effect and prognosis in elderly patients with stable coronary heart disease complicating non-valvular atrial fibrillation. IMHGN 2017; 23 (17) 2741-2744
    PubMedGoogle Scholar
  • 67 Qiao Y, Jia M, Xu D, Feng P, Ma X, Chen L. Efficacy and safety of different anticoagulant intensity of warfarin in AF patients with elderly age and type 2 diabetes mellitus. Zhonghua Linchuang Yishi Zazhi 2012; 6 (17) 5291-5292
    PubMedGoogle Scholar
  • 68 Qin P, Xuan C, Zhou Q. Prevention of ischemic stroke in AF patients treated with warfarin by age. Acta Acad Med Guangxi 2016; 33 (04) 691-693
    PubMedGoogle Scholar
  • 69 Shen L, Sun W, Zhang D, Wang W, Lu J. Safety and efficacy of different doses of warfarin anticoagulation therapy in non-valvular atrial fibrillation and risk factors associated with ischemic stroke. Chin J Mod Appl Pharm. 2016; 33 (06) 818-822
    PubMedGoogle Scholar
  • 70 Song Y. Effect of warfarin on elderly patients with type 2 diabetes complicated with atrial fibrillation. J Bengbu Med Coll. 2014; 39 (11) 1505-1507
    PubMedGoogle Scholar
  • 71 Sun Y. Effect of different intensity of anticoagulation in elderly patients with chronic nonvalvular atrial fibrillation. Chinese J Publ Health Eng 2017; 16 (06) 832-834
    PubMedGoogle Scholar
  • 72 Tang O, Cheng Y, Chen L. , et al. Effectivity and safety of low-intensity warfarin anticoagulation in patients with nonvascular atrial fibrillation aged 80 years old and over. Chin J Geriatr. 2011; 30 (02) 118-120
    PubMedGoogle Scholar
  • 73 Tong D, Wang J, Zhong Z. Low intensity of anticoagulation in AF patients for thromboprophylaxis. Preven Treat Cardio-Cerebral-Vascul Dis 2005; 5 (05) 22-24
    PubMedGoogle Scholar
  • 74 Wang R, Yan H, Yan Z, Wang X. Efficacy and safety of warfarin in aged patients with nonvalvular atrial fibrillation. Chin Heart J. 2008; 20 (02) 193-195
    PubMedGoogle Scholar
  • 75 Wang S, Hu H, Chen X, Wang J, Ye H. Different intensity warfarin in AF patients with atherosclerotic cardiovascular disease. Chinese J Clin Pharm Therapeut 2017; 22 (12) 1410-1414
    PubMedGoogle Scholar
  • 76 Wu X, Wang Z, Liu W. , et al. Effect and safety of low-dose warfarin in the treatment of elderly patients with stable coronary heart disease complicated with non-valvular atrial fibrillation. Med J Chinese People's Health 2019; 31 (07) 20-22
    PubMedGoogle Scholar
  • 77 Wu M, Fang S. Anticoagulant therapy of warfarin in patients with no-valvular heart disease and atrial fibrillation. Chinese J Cardiovasc Rehabil Med 2009; 18 (01) 65-67
    PubMedGoogle Scholar
  • 78 Wu J, Guo Y. Safety of different anticoagulant intensity of warfarin in AF patients aged over 80. The 4th National Conference of Senile Arteriosclerosis and Peripheral Vascular Disease; 2010: 85-89
    PubMedGoogle Scholar
  • 79 Wu Y, Li N, Xu B. Efficacy analysis of the different intensity of anticoagulation in patients with non-valvular atrial fibrillation. Guide China Med 2013; 11 (08) 41-42
    PubMedGoogle Scholar
  • 80 Xu H, He L. Prevention of stroke in low-dose warfarin and low-dose aspirin in patients with nonvalvular AF. J Bengbu Med Coll 2008; 33: 584-585
    PubMedGoogle Scholar
  • 81 Xu X, Wang B, Chen S. Warfarin and aspirin in elderly patients with paroxysmal AF. Chinese J Integrative Med Cardio Cerebrovasc Dis 2015; 13 (01) 118-119
    PubMedGoogle Scholar
  • 82 Yu L, Zhu L, Wang L. Prevention of stroke in low-dose anticoagulation combined with dual antiplatelet therapy in AF patients undergoing stenting. Chinese J Pract Nerv Dis 2016; 19 (22) 69-71
    PubMedGoogle Scholar
  • 83 Zeng J, Chen X, Jiang L, Peng Q, Su Y. Clinical study of different anticoagulant intensity of warfarin in prevention of nonvalvular atrial fibrillation. West China Med J 2009; 24 (01) 55-57
    PubMedGoogle Scholar
  • 84 Zhang D, Li Q, Liu Z. , et al. Clinical observation of different anticoagulant intensity of warfarin in prevention of thrombo-embolism on 212 patients with nonrheumatic. Prevent Treatment Cardio Cerebral Vasc Dis 2005; 5 (01) 16-18
    PubMedGoogle Scholar
  • 85 Zhang X, Wang J. Prevention of thrombotic events in low-dose warfarin in AF patients. Chinese Med 2006; 12: 712-713
    PubMedGoogle Scholar
  • 86 Zhang Y, Cao S. The randomized study of antithrombotic therapy with warfarin in elder patients with nonvascular atrial fibrillation. Effective Safe Anticoagul Intensity 2007; 9 (06) 491-492
    PubMedGoogle Scholar
  • 87 Zhang H, Chen X, Zhen R. , et al. Antithrombotic effect of warfarin with different anticoagulation intensities on prognosis of old patients with PAF. Chin J Geriatr Heart Brain Vessel Dis. 2009; 11 (10) 758-761
    PubMedGoogle Scholar
  • 88 Zhang J, Si H. Anticoagulation in atrial fibrillation. Nei Mongol J Traditional Chinese Med 2011; 2: 111-112
    PubMedGoogle Scholar
  • 89 Zhang D, Zhang H. Different INR range of warfarin therapy in elderly AF patients with stable coronary artery disease. Chongqing Med 2017; 46 (24) 3420-3421
    PubMedGoogle Scholar
  • 90 Zheng X, Mei X, Luo Y, Wu F. Anti-thrombus of different anticoagulating intensity of warfarin treatment on patients with atrial fibrillation. Chin J Cli Med Pract 2006; 5 (04) 303-304
    PubMedGoogle Scholar
  • 91 Zheng H, Li A, Cui H, Jin H, Wei Y, Zhu Y. Low-intensity warfarin in elderly patients with permanent AF. Chinese J Geriatr Heart Brain Vessel Dis 2009; 11 (10) 758-761
    PubMedGoogle Scholar
  • 92 Wang Y. Different INR ranges of warfarin therapy in elderly AF patients with stable coronary artery disease. J Aerospace Med 2018; 29 (03) 317-319
    PubMedGoogle Scholar
  • 93 He R, Cheng G, Hong Y. , et al. Therapeutic effect of warfarin on anticoagulation therapy in elderly patients with atrial fibrillation. Chin J Misdiagn 2006; 6 (17) 3347-3348
    PubMedGoogle Scholar
  • 94 Zhou B, Li Y, Luo X. , et al. The clinical study of warfarin anticoagulant therapy in elderly patients with stable coronary heart disease and nonvalvular atrial fibrillation. Med Innovation China 2019; 16 (16) 46-49
    PubMedGoogle Scholar
  • 95 Cai W, Wu P, Lin J. Clinical study of anticoagulation in atrial fibrillation combined with heart failure. Chin J Nat Med 2005; 7 (01) 3-5
    PubMedGoogle Scholar
  • 96 Ye D, Li Z. Effect of warfarin anticoagulation therapy on efficacy and prognosis in elderly patients with stable coronary heart disease and non valvular atrial fibrillation. Zhongguo Jiceng Yiyao 2018; 25 (20) 2590-2594
    PubMedGoogle Scholar
  • 97 Zhang W, Zhao J, Dai M. The clinical study of low anticoagulate intensity of warfarin to prevent thromboembolic complications in patients with nonvalvular atrial fibrillation. China Modern Doctor 2009; 47 (06) 25-28
    PubMedGoogle Scholar
  • 98 Liu T, Hui J, Hou YY. , et al. Meta-analysis of efficacy and safety of low-intensity warfarin therapy for East Asian patients with nonvalvular atrial fibrillation. Am J Cardiol 2017; 120 (09) 1562-1567
    CrossrefPubMedGoogle Scholar
  • 99 Wang H, Xu X, Huang P, Wang C. Efficacy and safety of warfarin with different anticoagulation intensities in treatment of nonvalvular atrial fibrillation: meta-analysis. Acad J Second Military Med Univ 2016; 37 (02) 256-261
    PubMedGoogle Scholar
  • 100 Singer DE, Hellkamp AS, Piccini JP. , et al; ROCKET AF Investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013; 2 (01) e000067
    PubMedGoogle Scholar
  • 101 Wallentin L, Yusuf S, Ezekowitz MD. , et al; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376 (9745): 975-983
    CrossrefPubMedGoogle Scholar
  • 102 Wallentin L, Lopes RD, Hanna M. , et al; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013; 127 (22) 2166-2176
    CrossrefPubMedGoogle Scholar
  • 103 Shimada YJ, Yamashita T, Koretsune Y. , et al. Effects of regional differences in Asia on efficacy and safety of edoxaban compared with warfarin--insights from the ENGAGE AF-TIMI 48 trial. Circ J 2015; 79 (12) 2560-2567
    CrossrefPubMedGoogle Scholar
  • 104 Schein JR, White CM, Nelson WW, Kluger J, Mearns ES, Coleman CI. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J 2016; 14 (01) 14
    CrossrefPubMedGoogle Scholar
  • 105 Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124 (01) 37-41
    CrossrefPubMedGoogle Scholar
  • 106 Connolly SJ, Pogue J, Eikelboom Jet al. ; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037
    CrossrefPubMedGoogle Scholar
  • 107 Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS One 2017; 12 (11) e0188482
    CrossrefPubMedGoogle Scholar
  • 108 White CM. INR stability, clinical importance, and predictors in patients with atrial fibrillation and venous thromboembolism receiving vitamin K antagonists. J Pharm Technol 2016; 32 (06) 253-259
    PubMedGoogle Scholar
  • 109 Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50 (04) 309-315
    CrossrefPubMedGoogle Scholar
  • 110 Ogawa S, Aizawa Y, Atarashi H. , et al. Guidelines for pharmacotherapy of atrial fibrillation. Circ J 2008; 72 (Suppl IV): 1639-1658
    PubMedGoogle Scholar
  • 111 Dalal J, Bhave A, Oomman A. , et al; SPAF Academy India experts. The Indian consensus guidance on stroke prevention in atrial fibrillation: an emphasis on practical use of nonvitamin K oral anticoagulants. Indian Heart J 2015; 67 (Suppl. 02) S13-S34
    PubMedGoogle Scholar
  • 112 Ogawa S, Aonuma K, Tse HF. , et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythm 2013; 29 (03) 190-200
    PubMedGoogle Scholar
  • 113 Chiang CE, Wu TJ, Ueng KC. , et al. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc 2016; 115 (11) 893-952
    CrossrefPubMedGoogle Scholar
  • 114 Ogawa S, Aonuma K, Huang D. , et al. Fact-finding survey of antithrombotic treatment for prevention of cerebral and systemic thromboembolism in patients with non-valvular atrial fibrillation in 9 countries of the Asia-Pacific region. J Arrhythm 2012; 28 (01) 41-55
    PubMedGoogle Scholar
  • 115 Yasaka M, Lip GY. Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation. Circ J 2014; 78 (10) 2367-2372
    CrossrefPubMedGoogle Scholar
  • 116 Bang OY, Hong KS, Heo JH. , et al. New oral anticoagulants may be particularly useful for Asian stroke patients. J Stroke 2014; 16 (02) 73-80
    CrossrefPubMedGoogle Scholar